In this piece, we will look at the stocks Jim Cramer recently discussed.

Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Shares of Merck & Co. Inc. fell more than 0.5% on Monday afternoon, tracking their fifth consecutive decline in the worst ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.